Ventricular Dysfunction, Left
0
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
BioVentrixRevivent TC
Colorado TherapeuticsLVAD
Orion PharmaLevosimendan
Clinical Trials (3)
Total enrollment: 165 patients across 3 trials
BioVentrix Revivent TC™ System Clinical Study
Start: Aug 2017Est. completion: Jun 2027126 patients
N/AActive Not Recruiting
Characterization of the Plasma Proteome Following Left Ventricular Assist Device Implantation
Start: Oct 2014Est. completion: Jan 201720 patients
N/ACompleted
Preoperative levosimendán and Hip Fracture
Start: May 2014Est. completion: Apr 201919 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.